Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 2:15:17588359231187202.
doi: 10.1177/17588359231187202. eCollection 2023.

Novel radionuclide therapy combinations in prostate cancer

Andrisha-Jade Inderjeeth  1   2 , Amir Iravani  3 , Shalini Subramaniam  4   5 , Ciara Conduit  1   2   6 , Shahneen Sandhu  7   6
Affiliations
Review

Novel radionuclide therapy combinations in prostate cancer

Andrisha-Jade Inderjeeth et al. Ther Adv Med Oncol. .

Abstract

Prostate cancer remains the commonest cancer diagnosed in males and a leading cause of cancer-related death. Men with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on chemotherapy and androgen receptor pathway inhibitors (ARPI) have limited treatment options, significant morbidity, and poor outcomes. Prostate-specific membrane antigen (PSMA)-directed radionuclide therapy (RNT) is emerging as an efficacious and well-tolerated therapy; however, disease progression is universal. Several ongoing RNT trials focus on combination strategies to improve efficacy and durability of treatment response, including combinations with ARPIs, chemotherapy, immunotherapy, and targeted therapies. Further, efforts are underway to expand the role of PSMA-directed RNT to earlier stages of disease including hormone-sensitive and localized prostate cancer. In this review, we discuss the rationale and ongoing RNT combination therapeutic trials in prostate cancer and summarize the efficacy and toxicity associated with RNT.

Keywords: prostate cancer; radiation; radioligand therapy; radionuclide therapy; theranostics.

PubMed Disclaimer

References

    1. International WCRF. Prostate cancer statistics 2020, https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/
    1. Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. - PubMed
    1. Wang L, Lu B, He M, et al.. Prostate cancer incidence and mortality: Global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health 2022; 10: 811044. - PMC - PubMed
    1. Wright GL, Jr., Haley C, Beckett ML, et al.. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1995; 1: 18–28. - PubMed
    1. Sartor O, de Bono J, Chi KN, et al.. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385: 1091–1103. - PMC - PubMed

LinkOut - more resources